These isogenic knockdown and pathway inhibition experiments control for genetic complexities between PDAC and OS tumor cells versus normal cells, clearly demonstrating that expression of MYC and KRAS oncogenes drives the ISG suppression phenotype that was identified using unbiased proteomics. The gene discussed is KRAS; the disease is neoplasm.